# CITATION REPORT List of articles citing

Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation

DOI: 10.1128/aac.49.6.2276-2282.2005 Antimicrobial Agents and Chemotherapy, 2005, 49, 2276-82.

Source: https://exaly.com/paper-pdf/38973538/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
220	From the New Editors. <b>2000</b> , 11, 3-3		
219	Crosstalk between antibiotic resistance and virulence in Pseudomonas aeruginosa. <b>2005</b> , 16, 155-161		2
218	Hypermutable bacteria isolated from humansa critical analysis. <b>2006</b> , 152, 2505-2514		63
217	Sequence variability and functional analysis of MutS of hypermutable Pseudomonas aeruginosa cystic fibrosis isolates. <b>2006</b> , 296, 313-20		12
216	Evolution of mutation rates in bacteria. <b>2006</b> , 60, 820-7		251
215	PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. <b>2006</b> , 62, 84-99		82
214	Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients. <b>2006</b> , 74, 4708-14		28
213	Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 975-83	5.9	68
212	Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. <b>2006</b> , 43 Suppl 2, S100-5		127
211	Radiation Risk Estimates in Normal and Emergency Situations. 2006,		
210	Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. <b>2007</b> , 189, 3665-8		41
209	Microbial ecology of the cystic fibrosis lung. <b>2007</b> , 153, 917-923		249
208	Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. <b>2007</b> , 195, 70-80		97
207	Social cheating in Pseudomonas aeruginosa quorum sensing. <b>2007</b> , 104, 15876-81		360
206	High relatedness selects against hypermutability in bacterial metapopulations. <b>2007</b> , 274, 1341-7		18
205	Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. <b>2007</b> , 153, 1852-1859		54
204	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 2574-81	5.9	33

#### (2008-2007)

203	Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. <b>2007</b> , 153, 1445-1454		70
202	Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 4531-2	5.9	8
201	Efflux pumps as antimicrobial resistance mechanisms. <b>2007</b> , 39, 162-76		336
200	Pseudomonas aeruginosa and the host pulmonary immune response. <b>2007</b> , 1, 121-37		5
199	The microbiology of mutability. <b>2007</b> , 277, 11-20		43
198	Silver against Pseudomonas aeruginosa biofilms. <b>2007</b> , 115, 921-8		157
197	Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients. <b>2008</b> , 27, 1093-9		16
196	Pseudomonas aeruginosa deficient in 8-oxodeoxyguanine repair system shows a high frequency of resistance to ciprofloxacin. <b>2009</b> , 290, 217-26		15
195	Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. <b>2008</b> , 7, 391-7		124
194	Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. <b>2008</b> , 7, 523-30		178
193	What makes pathogens pathogenic. <b>2008</b> , 9, 225		46
192	Application and evaluation of double digest selective label (DDSL) typing technique for Pseudomonas aeruginosa hospital isolates. <b>2008</b> , 72, 283-7		12
191	Innate immune activation and cystic fibrosis. 2008, 9, 271-9; quiz 279-80		23
190	Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. <b>2008</b> , 46, e137-41		29
189	Antibiotic Policies: Fighting Resistance. 2008,		3
188	Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 1057-61	5.1	20
187	Increased mutability of Pseudomonas aeruginosa in biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 1053-6	5.1	149
186	Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. <b>2008</b> , 46, 3491-3		49

185	Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. <b>2008</b> , 190, 7910-7		182
184	Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 3810-3	5.9	26
183	The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 2183-9	5.9	62
182	Clinical Relevance of Pseudomonas aeruginosa: A Master of Adaptation and Survival Strategies. 25-44		1
181	Role of mutation in Pseudomonas aeruginosa biofilm development. <b>2009</b> , 4, e6289		88
180	Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 64, 1241-50	5.1	19
179	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1552-60	5.9	63
178	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2483	3- <del>5</del> 9	76
177	Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. <b>2009</b> , 44, 547-58		542
176	Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. <b>2009</b> , 44, 820-5		48
175	The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa. <b>2009</b> , 294, 89-96		30
174	Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. <b>2009</b> , 117, 95-107		41
173	Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. <b>2009</b> , 17, 130-8		136
172	Genomewide identification of genetic determinants of antimicrobial drug resistance in Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2522-31	5.9	80
171	Guidance document on the submission of data for the evaluation of the safety and efficacy of substances for the removal of microbial surface contamination of foods of animal origin intended for human consumption. <b>2010</b> , 8, 1544		20
170	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. <b>2010</b> , 16, 1482-1487		27
169	Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. <b>2010</b> , 16, 798-808		120
168	Cellular responses of A549 alveolar epithelial cells to serially collected Pseudomonas aeruginosa from cystic fibrosis patients at different stages of pulmonary infection. <b>2010</b> , 59, 207-20		30

## (2011-2010)

167	Mechanisms of stationary-phase mutagenesis in bacteria: mutational processes in pseudomonads. <b>2010</b> , 312, 1-14		31
166	Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. <b>2010</b> , 5, e12669		69
165	Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. <b>2010</b> , 59, 472-481		85
164	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1399-404	5.1	34
163	Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1160-4	5.9	104
162	Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. <b>2010</b> , 156, 1108-1119		132
161	Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. <b>2010</b> , 65, 57-62		130
160	Pseudomonas aeruginosa biofilms in cystic fibrosis. <b>2010</b> , 5, 1663-74		419
159	Antibiotic resistance of bacterial biofilms. <b>2010</b> , 35, 322-32		2148
158	Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy. <b>2010</b> , 300, 563-72		62
157	Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. <b>2010</b> , 14, 117-30		95
156	Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. <b>2010</b> , 5, e10115		172
155	Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. <b>2010</b> , 285, 30516-22		62
154	Clinical significance of microbial infection and adaptation in cystic fibrosis. <b>2011</b> , 24, 29-70		271
153	Targeting airway inflammation in cystic fibrosis in children: past, present, and future. <b>2011</b> , 13, 141-7		18
152	Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. <b>2013</b> , 358, 91-118		84
151	Resistance of bacterial biofilms to disinfectants: a review. <b>2011</b> , 27, 1017-32		513
150	Biofilm Infections. <b>2011</b> ,		24

149	The role of bacterial biofilm in persistent infections and control strategies. 2011, 3, 66-73		146
148	Bacterial hypermutation: clinical implications. <b>2011</b> , 60, 563-573		62
147	Antibiotic and metal resistance among hospital and outdoor strains of Pseudomonas aeruginosa. <b>2011</b> , 162, 689-700		53
146	Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. <b>2011</b> , 10, 387-400		23
145	Epistatic roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage. <b>2011</b> , 6, e18824		13
144	Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. <b>2011</b> , 6, e27842		43
143	Importance of Adaptive and Stepwise Changes in the Rise and Spread of Antimicrobial Resistance. <b>2011</b> , 43-71		3
142	Microbial ecology and adaptation in cystic fibrosis airways. <b>2011</b> , 13, 1682-9		51
141	Development of antibiotic resistance and up-regulation of the antimutator gene pfpl in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM). <b>2011</b> , 324, 28-37		15
140	Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. <b>2011</b> , 35, 124-46		73
139	Breaking the rules: bacteria that use several DNA polymerase IIIs. <b>2011</b> , 12, 408-14		37
138	Low pesticide rates may hasten the evolution of resistance by increasing mutation frequencies. <b>2011</b> , 67, 253-7		97
137	Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 1068-74	5.9	84
136	Evolutionary dynamics of bacteria in a human host environment. <b>2011</b> , 108, 7481-6		<b>2</b> 60
135	Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 5230-7	5.9	45
134	Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia. <b>2011</b> , 2011, 852513		24
133	Phosphorothioate DNA as an antioxidant in bacteria. <b>2012</b> , 40, 9115-24		61
132	Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. <b>2012</b> , 205, 121-7		49

## (2013-2012)

131	Polymicrobial challenges to Kochß postulates: ecological lessons from the bacterial vaginosis and cystic fibrosis microbiomes. <b>2012</b> , 18, 774-83	26
130	Stress responses as determinants of antimicrobial resistance in Gram-negative bacteria. <b>2012</b> , 20, 227-34	134
129	Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa. <b>2012</b> , 194, 5315-24	14
128	Antimicrobials as promoters of genetic variation. <b>2012</b> , 15, 561-9	117
127	Efflux-Mediated Antimicrobial Resistance. <b>2012</b> , 349-395	9
126	Bacterial stress responses as determinants of antimicrobial resistance. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2069-89	279
125	Effect of organic matter on the in vitro photoeradication of Pseudomonas aeruginosa by means of a cationic tetraaryl-porphyrin. <b>2012</b> , 88, 557-64	18
124	Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. <b>2012</b> , 65, 215-25	61
123	Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis. <b>2013</b> , 13, 143	21
122	The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. <b>2013</b> , 7, 385-96	11
121	The antioxidant resveratrol down-regulates inflammation in an in-vitro model of Pseudomonas aeruginosa infection of lung epithelial cells. <b>2013</b> , 91, 248-55	16
120	Applying insights from biofilm biology to drug development - can a new approach be developed?. <b>2013</b> , 12, 791-808	340
119	P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. <b>2013</b> , 12, 729-36	52
118	Hypermutable Staphylococcus aureus strains present at high frequency in subclinical bovine mastitis isolates are associated with the development of antibiotic resistance. <b>2013</b> , 165, 410-5	15
117	Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 4215-21	75
116	Genome analysis of a transmissible lineage of pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. <b>2013</b> , 9, e1003741	146
115	Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities. <b>2013</b> , 51, 927-30	8
114	A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. <b>2013</b> , 280, 20130007	32

113	nfxB as a novel target for analysis of mutation spectra in Pseudomonas aeruginosa. 2013, 8, e66236	16
112	Swimming motility in a longitudinal collection of clinical isolates of Burkholderia cepacia complex bacteria from people with cystic fibrosis. <b>2014</b> , 9, e106428	15
111	Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections. <b>2014</b> , 2014, 389629	22
110	Evolution of Antibiotic Resistance by Hypermutation. <b>2014</b> , 319-331	
109	Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. <b>2014</b> , 10, e1004651	76
108	Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator. <b>2015</b> , 73, 1-14	32
107	Overexpression of CupB5 activates alginate overproduction in Pseudomonas aeruginosa by a novel AlgW-dependent mechanism. <b>2014</b> , 93, 415-25	6
106	Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities. <b>2014</b> , 122, 1-51	73
105	Stress responses as determinants of antimicrobial resistance in Pseudomonas aeruginosa: multidrug efflux and more. <b>2014</b> , 60, 783-91	39
104	Involvement of stress-related genes polB and PA14_46880 in biofilm formation of Pseudomonas aeruginosa. <b>2014</b> , 82, 4746-57	4
103	Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. <b>2014</b> , 304, 613-9	21
102	Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. <b>2014</b> , 304, 1182-91	19
101	Evolution of Pseudomonas aeruginosa Pathogenicity: From Acute to Chronic Infections. <b>2014</b> , 433-444	7
100	Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review. <b>2014</b> , 3, 680-703	148
99	Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. <b>2015</b> , 16, 883	25
98	Nutritional Strategies to Modulate Inflammation and Oxidative Stress in Patients with Cystic Fibrosis. <b>2015</b> , 145-153	
97	Chronic Infection with Pseudomonas aeruginosa in an Animal Model of Oxidative Stress. <b>2015</b> , 171-178	
96	Within-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients. <b>2015</b> , 15, 218	39

## (2016-2015)

95	Synthesis and structure-activity relationships of novel cationic lipids with anti-inflammatory and antimicrobial activities. <b>2015</b> , 25, 2837-43		4
94	Antioxidant Hydroxytyrosol-Based Polyacrylate with Antimicrobial and Antiadhesive Activity Versus Staphylococcus Epidermidis. <b>2016</b> , 901, 25-36		8
93	The problems of antibiotic resistance in cystic fibrosis and solutions. <b>2015</b> , 9, 73-88		30
92	Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection. <b>2015</b> , 14, e1-2		3
91	The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in mice. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4067-73	5.9	58
90	NHEJ enzymes LigD and Ku participate in stationary-phase mutagenesis in Pseudomonas putida. <b>2015</b> , 31, 11-8		13
89	Evolutionary insight from whole-genome sequencing of Pseudomonas aeruginosa from cystic fibrosis patients. <b>2015</b> , 10, 599-611		31
88	Diversity of metabolic profiles of cystic fibrosis Pseudomonas aeruginosa during the early stages of lung infection. <b>2015</b> , 161, 1447-62		16
87	Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. <b>2015</b> , 85, 7-23		181
86	Biofilm-associated persistence of food-borne pathogens. <b>2015</b> , 45, 167-78		257
85	Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. <b>2015</b> , 47, 57-64		337
84	Conditional probability analysis of multidrug resistance in Gram-negative bacilli isolated from tertiary medical institutions in South Korea during 1999-2009. <b>2016</b> , 54, 50-56		6
84			1
	tertiary medical institutions in South Korea during 1999-2009. <b>2016</b> , 54, 50-56		
83	tertiary medical institutions in South Korea during 1999-2009. <b>2016</b> , 54, 50-56  Genome Instability in Bacteria. <b>2016</b> , 69-85		1
8 <sub>3</sub>	Genome Instability in Bacteria. <b>2016</b> , 69-85  Bacterial Stress Responses as Determinants of Antimicrobial Resistance. <b>2016</b> , 115-136		5
8 <sub>3</sub> 8 <sub>2</sub> 8 <sub>1</sub>	tertiary medical institutions in South Korea during 1999-2009. 2016, 54, 50-56  Genome Instability in Bacteria. 2016, 69-85  Bacterial Stress Responses as Determinants of Antimicrobial Resistance. 2016, 115-136  Metabolic flux analyses of Pseudomonas aeruginosa cystic fibrosis isolates. 2016, 38, 251-263  Nutrient reduction induced stringent responses promote bacterial quorum-sensing divergence for		<ul><li>1</li><li>5</li><li>6</li></ul>

77	The properties of spontaneous mutations in the opportunistic pathogen Pseudomonas aeruginosa. <b>2016</b> , 17, 27	52
76	Anionic fluoroquinolones as antibacterials against biofilm-producing Pseudomonas aeruginosa. <b>2016</b> , 26, 1305-9	11
75	Chronic pulmonary pseudomonal infection in patients with cystic fibrosis: A model for early phase symbiotic evolution. <b>2016</b> , 42, 144-57	10
74	Rapid adaptation drives invasion of airway donor microbiota by Pseudomonas after lung transplantation. <b>2017</b> , 7, 40309	21
73	Antibiotic treatment of biofilm infections. <b>2017</b> , 125, 304-319	175
72	Pseudomonas. <b>2017</b> , 899-922	1
71	A single point mutation in class III ribonucleotide reductase promoter renders Pseudomonas aeruginosa PAO1 inefficient for anaerobic growth and infection. <b>2017</b> , 7, 13350	8
70	Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. <b>2017</b> , 307, 353-362	54
69	Investigation on the effect of known potent S. aureus NorA efflux pump inhibitors on the staphylococcal biofilm formation. <b>2017</b> , 7, 37007-37014	20
68	Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone. <b>2017</b> , 7, 5555	64
67	Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <b>2017</b> , 16, 222-229	26
66	Intermolecular interaction and solid state characterization of abietic acid/chitosan solid dispersions possessing antimicrobial and antioxidant properties. <b>2018</b> , 125, 114-123	25
65	New Perspectives in Biofilm Eradication. <b>2018</b> , 4, 93-106	87
64	Heterogeneous Antimicrobial Susceptibility Characteristics in Isolates from Cystic Fibrosis Patients. <b>2018</b> , 3,	13
63	The Microbial Endocrinology of Pseudomonas aeruginosa: Inflammatory and Immune Perspectives. <b>2018</b> , 66, 329-339	5
62	Hypermutation-induced in vivo oxidative stress resistance enhances Vibrio cholerae host adaptation. <b>2018</b> , 14, e1007413	19
61	Long-Term Colonization Dynamics of Enterococcus faecalis in Implanted Devices in Research Macaques. <b>2018</b> , 84,	1
60	Gender differences in bronchiectasis: a real issue?. <b>2018</b> , 14, 108-121	30

#### (2021-2019)

59	Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	6
58	Seeding Public Goods Is Essential for Maintaining Cooperation in. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 2322	5.7	3
57	The Essential Role of Hypermutation in Rapid Adaptation to Antibiotic Stress. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	15
56	An Additive Manufacturing Approach that Enables the Field Deployment of Synthetic Biosensors. <b>2019</b> , 5, 173-180		2
55	The effect of bacterial mutation rate on the evolution of CRISPR-Cas adaptive immunity. <b>2019</b> , 374, 20	018009	4 16
54	An £lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa. <b>2019</b> , 25, 28-33		2
53	Primary ciliary dyskinesia patients have the same clone in sinuses and lungs. 2020, 55,		2
52	In vitro immune responses of bovine mammary epithelial cells induced by Escherichia coli, with multidrug resistant extended-spectrum 🛭 actamase, isolated from mastitic milk. <b>2020</b> , 149, 104494		1
51	The sino-nasal warzone: transcriptomic and genomic studies on sino-nasal aspergillosis in dogs. <b>2020</b> , 6, 51		2
50	Individual Nudix hydrolases affect diverse features of Pseudomonas aeruginosa. <b>2020</b> , 9, e1052		3
49	CFTR Regulates the Proliferation, Migration and Invasion of Cervical Cancer Cells by Inhibiting the NF- <b>B</b> Signalling Pathway. <b>2020</b> , 12, 4685-4697		7
48	Prevalence of hypermutator isolates of Achromobacter spp. from cystic fibrosis patients. <b>2020</b> , 310, 151393		4
47	Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations. <b>2020</b> , 14, 1929-1942		16
46	Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	20
45	Biofilm and Antimicrobial Resistance. <b>2021</b> , 183-208		O
44	Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis. <b>2021</b> , 78, 696-704		1
43	Genome instability in bacteria: Causes and consequences. <b>2021</b> , 73-90		О
42	Compensatory evolution of Pseudomonas aeruginosa® slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis. <b>2021</b> , 12, 3186		7

Development of antibiotic resistance reveals diverse evolutionary pathways to face the complex and dynamic environment of a long-term treated patient.

40	Genomic and Phenotypic Evolution of Achromobacter xylosoxidans during Chronic Airway Infections of Patients with Cystic Fibrosis. <b>2021</b> , e0052321	O
39	The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects. 2021, 30,	5
38	Oxidative Stress Response in. <b>2021</b> , 10,	3
37	Cystic Fibrosis©oping with Resistance. <b>2008</b> , 149-174	2
36	Pseudomonas aeruginosa Biofilms in the Lungs of Cystic Fibrosis Patients. <b>2011</b> , 167-184	3
35	Antibiotic Tolerance and Resistance in Biofilms. <b>2010</b> , 215-229	9
34	Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation. <b>2019</b> , 68, 446-455	6
33	MexXY RND pump of PA7 effluxes bi-anionic Elactams carbenicillin and sulbenicillin when it partners with the outer membrane factor OprA but not with OprM. <b>2020</b> , 166, 1095-1106	6
32	Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations.	1
31	Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients.	O
30	Pseudomonas. 773-790	5
29	Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. <b>2013</b> , 8, e71001	47
28	Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. <b>2014</b> , 9, e86705	55
27	Role of Antioxidant Molecules and Polymers in Prevention of Bacterial Growth and Biofilm Formation. <b>2020</b> , 27, 4882-4904	2
26	Adaptation and genomic erosion in fragmented Pseudomonas aeruginosa populations in the sinuses of people with cystic fibrosis. <b>2021</b> , 37, 109829	3
25	Innate Immune Response to Infectious Biofilms. <b>2011</b> , 185-200	
24	Molecular Life Sciences. <b>2014</b> , 1-5	

DivergentIn vitroMIC Characteristics and underlying isogenic mutations in 23 host-specializedPseudomonas aeruginosa. Molecular Life Sciences. 2018, 652-655 22 Agmatine accumulation by Pseudomonas aeruginosaclinical isolates confers antibiotic tolerance 21 and dampens host inflammation. The essential role of hypermutation in rapid adaptation to antibiotic stress. MODULATION OF MUTATION RATES AND ADAPTATION OF BACTERIA. 2006, 309-317 19 Evolution and adaptation of Pseudomonas aeruginosain the paranasal sinuses of people with cystic 18 fibrosis. The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related 17 2.4 1 diabetes.. Journal of Clinical and Translational Endocrinology, 2022, 27, 100287 16 Mutators Enhance Adaptive Micro-Evolution in Pathogenic Microbes.. Microorganisms, 2022, 10, 4.9 Virulence Mechanisms of: Current Knowledge and Implications for Vaccine Design.. Frontiers in 15 5.7 1 Microbiology, 2022, 13, 842017 Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European 5.1 14 ICUs participating in the ASPIRE-ICU trial.. Journal of Antimicrobial Chemotherapy, 2022, Assessing the importance of resistance, persistence and hyper-mutation for antibiotic treatment 13 1 success with stochastic modelling. Data\_sheet\_1.docx. 2019, 12 Table\_1.DOCX. 2019, 11 Table\_2.DOCX. **2019**, 10 Links between Disease Severity, Bacterial Infections and Oxidative Stress in Cystic Fibrosis. 9 7.1 Antioxidants, 2022, 11, 887 Emergence of a Pseudomonas aeruginosa Hypermutator Strain During the Course of Ventilator-Associated Pneumonia. Time Series Genomics of Pseudomonas aeruginosa Reveals the Emergence of a Hypermutator 8.9 Phenotype and Within-Host Evolution in Clinical Inpatients. Microbiology Spectrum,

The role of the Pseudomonas aeruginosa hypermutator phenotype on the shift from acute to

chronic virulence during respiratory infection. Frontiers in Cellular and Infection Microbiology, 12,

5.9

5	Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung. <b>2022</b> , 11, S23-S31	2
4	Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with £Lactams.	1
3	Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure. <b>2022</b> , 289,	О
2	Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors. <b>2022</b> , 20, e3001878	O
1	Spatial heterogeneity in biofilm metabolism elicited by local control of phenazine methylation.	0